Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
Public ClinicalTrials.gov record NCT01963611. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for minimum treatment duration of 40 weeks.
Study identification
- NCT ID
- NCT01963611
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 255 participants
Conditions and interventions
Conditions
Interventions
- Plovamer acetate 0.5 milligram (mg) Drug
- Copaxone 20 mg Drug
- Plovamer acetate 3 mg Drug
- Plovamer acetate 10 mg Drug
- Plovamer acetate 20 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2013
- Primary completion
- Feb 28, 2015
- Completion
- Feb 28, 2015
- Last update posted
- May 10, 2016
2013 – 2015
United States locations
- U.S. sites
- 35
- U.S. states
- 20
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research site | Redding | California | 96001 | — |
| Research site | San Diego | California | 92117 | — |
| Research site | San Diego | California | 92128 | — |
| Research site | Fairfield | Connecticut | 06824 | — |
| Research site | Dover | Delaware | 19901 | — |
| Research site | Miami | Florida | 33136 | — |
| Research site | Naples | Florida | 34102 | — |
| Research site | Pompano Beach | Florida | 33060 | — |
| Research site | Sarasota | Florida | 34233 | — |
| Research site | Sunrise | Florida | 33351 | — |
| Research site | Columbus | Georgia | 31909 | — |
| Research site | Rome | Georgia | 30165 | — |
| Research site | Elk Grove Village | Illinois | 60007 | — |
| Research site | Indianapolis | Indiana | 46256 | — |
| Research site | Baltimore | Maryland | 21287 | — |
| Research site | New Bedford | Massachusetts | 02740 | — |
| Research site | Worcester | Massachusetts | 01655 | — |
| Research site | Detroit | Michigan | 48202-2689 | — |
| Research Site | Detroit | Michigan | 97205 | — |
| Research site | Golden Valley | Minnesota | 55422 | — |
| Research site | St Louis | Missouri | 63110 | — |
| Research site | Plainview | New York | 11803 | — |
| Research site | Charlotte | North Carolina | 28209 | — |
| Research site | Hickory | North Carolina | 28602 | — |
| Research site | Matthews | North Carolina | 28105 | — |
| Research site | Raleigh | North Carolina | 27607-6010 | — |
| Research site | Wilmington | North Carolina | 28401 | — |
| Research site | Cincinnati | Ohio | 45206 | — |
| Research site | Dayton | Ohio | 45417 | — |
| Research site | Willow Grove | Pennsylvania | 19090 | — |
| Research site | Nashville | Tennessee | 37205 | — |
| Research Site | Round Rock | Texas | 78681 | — |
| Research Site | San Antonio | Texas | 78258 | — |
| Research site | Roanoke | Virginia | 24018 | — |
| Research site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01963611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2016 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01963611 live on ClinicalTrials.gov.